Stocks To Watch: Boston Scientific Corporation (BSX), Delta Air Lines, Inc. (DAL), Reynolds American Inc. (RAI)

Boston Scientific Corporation (BSX) traded within a range of $25.13 to $25.52 after opening the day at $25.43. The company has seen its stock increase in value by 17.24% so far this year. The stock was down close to -0.2% on light volume in last trading session and closed at $25.36 per share. After the recent fall, the stock is currently holding -1.13% below its 52 week high of $25.65 and 52.59% above its 12-month low of $16.82. The shares are up by over 19.96% in the last three months, and the RSI indicator value of 74.38 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Delta Air Lines, Inc. (DAL) failed to extend gains with the stock declining -0.66% or $-0.34 to close the day at $50.83 on light trading volume of 6.61M shares, compared to its three month average trading volume of 7.63M. The Atlanta Georgia 30354 based company has been outperforming the major airlines group over the past 52 weeks, with the stock gaining 10.87%, compared to the industry which has advanced 18.31% over the same period. With RSI of 58.85, the stock should still continue to rise and get closer to its one year target estimate of $0, making it a hold for now.

Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its route network is centered around a system of hubs, international gateways, and airports in Amsterdam, Atlanta, Boston, Detroit, London-Heathrow, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including delta.com and mobile applications/Web, telephone reservations, online travel agencies, traditional brick and mortar, and other agencies. It also provides aircraft maintenance, repair, and overhaul services; staffing, and professional security and training services, as well as aviation solutions to third parties; vacation packages to third-party consumers; and aircraft charters, and aircraft management and programs. As of February 2, 2017, the company operated a fleet of approximately 800 aircraft. Delta Air Lines, Inc. was founded in 1924 and is headquartered in Atlanta, Georgia.

Reynolds American Inc. (RAI) gained $0.28 to close the day at a new closing price of $60.71, a 0.46% increase in value from its previous closing price that moved the stock 41.12% above its 52 week low of $43.38. A total of 6.55M shares exchanged hands during the day compared with its three month average trading volume of 7.46M. The stock, which fluctuated between $60.27 and $60.83 during the day, currently situated -0.33% below its 52 week high. The stock is up by 4.67% in the past one month and up by 14.06% over the past three months. With a one year target estimate of $57.01 and RSI of 71.62, the stock still has upside potential, making it a sell for now.

Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.

 

3 Stocks to Watch For: Boston Scientific Corporation (BSX), Expedia, Inc. (EXPE), Crown Castle International Corp. (CCI)

Boston Scientific Corporation (BSX) saw its value decrease by -0.47% as the stock dropped $-0.12 to finish the day at a closing price of $25.18. The stock was higher in trading and has fluctuated between $16.82-$25.45 per share for the past year. The shares, which traded within a range of $24.98 to $25.29 during the day, are up by 17.12% in the past three months and up by 5.05% over the past six months. It is currently trading 3.34% above its 20 day moving average and 10.74% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $28.12 a share over the next twelve months. The current relative strength index (RSI) reading is 73.81.The technical indicator do not lead us to believe the stock will see more gains any time soon.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Expedia, Inc. (EXPE) shares were up in last trading by 0.14% to $119.67. It experienced higher than average volume on day. The stock decreased in value by almost -2.18% over the past week and grew 0.72% in the past month. It is currently trading 0.6% above its 50 day moving average and 3.38% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -10.2% decrease in value from its one year high of $133.55. The RSI indicator value of 46.82, lead us to believe that it is a hold for now.

Expedia, Inc., together with its subsidiaries, operates as an online travel company in the United States and internationally. The company operates through four segments: Core OTA, Trivago, Egencia, and HomeAway. It facilitates the booking of hotel rooms, airline seats, car rentals, and destination services from its travel suppliers; and acts as an agent in the transactions. The company serves leisure and corporate travelers, offline retail travel agents, and travel service providers through Expedia.com, Hotels.com, Hotwire.com, Wotif.com, Wotif.co.nz, lastminute.com.au, lastminute.com.nz, travel.com.au, CarRentals.com, and Orbitz.com Websites; and Travelocity, HomeAway, Egencia, trivago, Classic Vacations, Expedia Local Expert, and Expedia CruiseShipCenters brands, as well as Expedia Affiliate Network. It also engages in advertising and media business. The company was founded in 1996 and is headquartered in Bellevue, Washington.

Crown Castle International Corp. (CCI) traded within a range of $89.17 to $90.34 after opening the day at $90.03. The company has seen its stock increase in value by 4.01% so far this year. The stock was up close to 0.03% on light volume in last trading session and closed at $90.25 per share. After the recent gain, the stock is currently holding -10.4% below its 52 week high of $102.82 and 14.93% above its 12-month low of $79.38. The shares are up by over 10.92% in the last three months, and the RSI indicator value of 64.19 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Crown Castle International Corp., together with its subsidiaries, owns, operates, and leases shared wireless infrastructure in the United States and Australia. The company provides towers and other structures, such as rooftops; and distributed antenna systems, a type of small cell network (small cells). It provides access, including space or capacity to its towers, small cells, and third party land interests via long-term contracts in various forms, including license, sublease, and lease agreements. In addition, the company offers network services relating to wireless infrastructure, primarily consisting of antenna installations or subsequent augmentations, as well as site development services relating to wireless infrastructure. As of December 31, 2013, it owned, leased, or managed approximately 39,600 towers in the United States, including Puerto Rico; and approximately 1,700 towers in Australia. The company was founded in 1994 and is headquartered in Houston, Texas.

 

Stocks on Trader’s Radar: MetLife, Inc. (MET), Boston Scientific Corporation (BSX), Reynolds American Inc. (RAI)

MetLife, Inc. (MET) continued its upward trend with the stock climbing 0.63% or $0.33 to close the day at $52.91 on light trading volume of 4.98M shares, compared to its three month average trading volume of 6.4M. The New York New York 10166 based company has been outperforming the life insurance group over the past 52 weeks, with the stock gaining 55.53%, compared to the industry which has advanced 55.42% over the same period. With RSI of 45.34, the stock should still continue to rise and get closer to its one year target estimate of $59.86, making it a hold for now.

MetLife, Inc. provides life insurance, annuities, employee benefits, and asset management products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa. The company provides variable, universal, term, and whole life products; individual disability income products; personal lines property and casualty insurance, including private passenger automobile, homeowners, and personal excess liability insurance; and variable and fixed annuities for asset accumulation and distribution needs, as well as mutual funds and other securities products. It also offers group insurance products, such as variable, universal, and term life products; dental, group short- and long-term disability, and accidental death and dismemberment coverages; and voluntary and worksite products consisting of personal lines property and casualty insurance, as well as LTC, prepaid legal plans, and critical illness products. In addition, the company provides annuity and investment products comprising guaranteed interest products and other stable value products, income annuities, and separate account contracts for the investment management of defined benefit and defined contribution plan assets; and structured settlements and products to fund postretirement benefits and company-, bank- or trust-owned life insurance, as well as health insurance, group medical, credit insurance, endowment, retirement, and savings products. It serves individuals and corporations, as well as other institutions and their employees. The company sells its products through sales forces, third-party organizations, independent agents, and property and casualty specialists, as well as through career agency, bancassurance, direct marketing, brokerage, and e-commerce channels. MetLife, Inc. was founded in 1863 and is based in New York, New York.

Boston Scientific Corporation (BSX) fell -0.55% during last trading as the stock lost $-0.14 to finish the day at $25.2 with about 4.95M shares changing hands, compared to its three month average trading volume of 8.33M. The $34.5B market cap company, which fluctuated between $25.2 and $25.43 during the day, currently situated 53.66% above its 52 week low of $16.62 and -0.98% away from its one year high of $25.45. The RSI of 76.47 indicates the stock is overbought at the current levels, sell for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Reynolds American Inc. (RAI) saw its value increase by 0.05% as the stock gained $0.03 to finish the day at a closing price of $60.57. The stock was lighter in trading and has fluctuated between $43.38-$60.91 per share for the past year. The shares, which traded within a range of $60.4 to $60.67 during the day, are up by 12.01% in the past three months and up by 23.02% over the past six months. It is currently trading 2.18% above its 20 day moving average and 6.38% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $57.01 a share over the next twelve months. The current relative strength index (RSI) reading is 77.18. The technical indicator do not lead us to believe the stock will see more gains any time soon.

Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.

 

Traders Watch list: PayPal Holdings, Inc. (PYPL), Fifth Third Bancorp (FITB), Boston Scientific Corporation (BSX)

PayPal Holdings, Inc. (PYPL) saw its value increase by 2.15% as the stock gained $0.86 to finish the day at a closing price of $40.88. The stock was higher in trading and has fluctuated between $32.01-$44.52 per share for the past year. The shares, which traded within a range of $39.92 to $40.99 during the day, are down by -0.97% in the past three months and up by 7.3% over the past six months. It is currently trading 0.19% above its 20 day moving average and 1.75% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $46.83 a share over the next twelve months. The current relative strength index (RSI) reading is 55.32.The technical indicator lead us to believe there will be no major movement any time soon, hold.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

Fifth Third Bancorp (FITB) shares were down in last trading by -2.27% to $25.89. It experienced higher than average volume on day. The stock decreased in value by almost -1.33% over the past week and fell -3.25% in the past month. It is currently trading -2.82% below its 50 day moving average and 21.92% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -6.67% decrease in value from its one year high of $27.88. The RSI indicator value of 42.33, lead us to believe that it is a hold for now.

Fifth Third Bancorp operates as a diversified financial services company in the United States. It operates through four segments: Commercial Banking, Branch Banking, Consumer Lending, and Investment Advisors. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. The Branch Banking segment provides deposit and loan products to individuals and small businesses. This segment offers checking and savings accounts, home equity loans and lines of credit, credit cards, and loans for automobiles and personal financing needs. The Consumer Lending segment engages in direct lending activities that include origination, retention, and servicing of residential mortgage and home equity loans or lines of credit; and indirect lending activities, including loans to consumers through correspondent lenders and automobile dealers. The Investment Advisors segment provides various investment alternatives for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides asset management services; holistic strategies to affluent clients in wealth planning, investing, insurance, and wealth protection; and advisory services for institutional clients comprising states and municipalities. As of December 31, 2015, the company operated 1,254 full-service banking centers, including 95 Bank Mart locations, as well as 2,593 automated teller machines in 12 states throughout the Midwestern and Southeastern regions of the United States. Fifth Third Bancorp was founded in 1862 and is headquartered in Cincinnati, Ohio.

Boston Scientific Corporation (BSX) traded within a range of $25.15 to $25.32 after opening the day at $25.2. The company has seen its stock increase in value by 16.69% so far this year. The stock was up close to 0.04% on light volume in last trading session and closed at $25.24 per share. After the recent gain, the stock is currently holding -0.55% below its 52 week high of $25.38 and 61.07% above its 12-month low of $16.4. The shares are up by over 14.52% in the last three months, and the RSI indicator value of 80.64 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Trader’s Buzzers: Bristol-Myers Squibb Company (BMY), PayPal Holdings, Inc. (PYPL), Boston Scientific Corporation (BSX)

Bristol-Myers Squibb Company (BMY) traded within a range of $50.56 to $51.09 after opening the day at $50.65. The company has seen its stock decrease in value by -12.09% so far this year. The stock was up close to 0.51% on light volume in last trading session and closed at $51.04 per share. After the recent gain, the stock is currently holding -32.92% below its 52 week high of $77.12 and 10.93% above its 12-month low of $46.01. The shares are up by over 2.32% in the last three months, and the RSI indicator value of 43.13 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

PayPal Holdings, Inc. (PYPL) continued its upward trend with the stock climbing 0.38% or $0.15 to close the day at $39.74 on active trading volume of 8.17M shares, compared to its three month average trading volume of 7.19M. The San Jose California 95131 based company has been outperforming the credit services group over the past 52 weeks, with the stock gaining 13.32%, compared to the industry which has advanced 28.93% over the same period. With RSI of 41.48, the stock should still continue to rise and get closer to its one year target estimate of $46.83, making it a hold for now.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

Boston Scientific Corporation (BSX) dropped $-0.08 to close the day at a new closing price of $25.14, a -0.32% decrease in value from its previous closing price that moved the stock 60.43% above its 52 week low of $16.25. A total of 8.11M shares exchanged hands during the day compared with its three month average trading volume of 8.57M. The stock, which fluctuated between $24.85 and $25.18 during the day, currently situated -0.48% below its 52 week high. The stock is up by 14.01% in the past one month and up by 16.71% over the past three months. With a one year target estimate of $27.69 and RSI of 79.25, the stock still has upside potential, making it a sell for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Eye Catching Stocks: Netflix, Inc. (NFLX), Boston Scientific Corporation (BSX), BioMarin Pharmaceutical Inc. (BMRN)

Netflix, Inc. (NFLX) continued its downward trend with the stock declining -0.36% or $-0.51 to close the day at $140.71 on light trading volume of 4.38M shares, compared to its three month average trading volume of 7.37M. The Los Gatos California 95032 based company has been outperforming the catv systems group over the past 52 weeks, with the stock gaining 49.55%, compared to the industry which has advanced 18.9% over the same period. With RSI of 68.89, the stock should still continue to rise and get closer to its one year target estimate of $148.05, making it a hold for now.

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic Streaming, International Streaming, and Domestic DVD. It offer members with the ability to receive streaming content through a host of Internet-connected screens, including TVs, digital video players, television set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. It serves approximately 93 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.

Boston Scientific Corporation (BSX) climbed 0.88% during last trading as the stock added $0.21 to finish the day at $24.06 with about 6.52M shares changing hands, compared to its three month average trading volume of 8.32M. The $32.76B market cap company, which fluctuated between $23.69 and $24.07 during the day, currently situated 53.54% above its 52 week low of $15.67 and -2.94% away from its one year high of $24.79. The RSI of 73.3 indicates the stock is overbought at the current levels, sell for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

BioMarin Pharmaceutical Inc. (BMRN) saw its value increase by 2.44% as the stock gained $2.09 to finish the day at a closing price of $87.63. The stock was lighter in trading and has fluctuated between $62.12-$102.49 per share for the past year. The shares, which traded within a range of $84 to $88.1 during the day, are up by 8.01% in the past three months and down by -12.59% over the past six months. It is currently trading 1.82% above its 20 day moving average and 2.44% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $113.44 a share over the next twelve months. The current relative strength index (RSI) reading is 55.26. The technical indicator lead us to believe there will be no major movement any time soon, hold.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; and Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Kyndrisa, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 044, BMN 045, and BMN 053 for DMD treatment; cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis; and BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate for the treatment of hemophilia A. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as alpha-N-acetyglucosaminidase. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.

 

Stocks To Watch: Reynolds American Inc. (RAI), T-Mobile US, Inc. (TMUS), Boston Scientific Corporation (BSX)

Reynolds American Inc. (RAI) traded within a range of $60.17 to $60.47 after opening the day at $60.23. The company has seen its stock increase in value by 7.67% so far this year. The stock was up close to 0.28% on light volume in last trading session and closed at $60.34 per share. After the recent gain, the stock is currently holding 0.13% above its 52 week high of $60.47 and 40.26% above its 12-month low of $43.38. The shares are up by over 12.32% in the last three months, and the RSI indicator value of 85.99 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.

T-Mobile US, Inc. (TMUS) failed to extend gains with the stock declining -1.5% or $-0.95 to close the day at $62.42 on active trading volume of 6.29M shares, compared to its three month average trading volume of 3.89M. The Bellevue Washington 98006 based company has been outperforming the wireless communications group over the past 52 weeks, with the stock gaining 61.42%, compared to the industry which has advanced 17.44% over the same period. With RSI of 67.71, the stock should still continue to rise and get closer to its one year target estimate of $61, making it a hold for now.

T-Mobile US, Inc., together with its subsidiaries, provides mobile communications services for consumers and businesses in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, including smartphones, tablets, and other mobile communication devices, as well as accessories that are manufactured by various suppliers. The company offers services, devices, and accessories under the T-Mobile and MetroPCS brands through its owned and operated retail stores, as well as through its Websites. T-Mobile US, Inc. also sells its devices and accessories to dealers and other third party distributors for resale through independent third-party retail outlets and various third-party Websites. It delivers wireless services to approximately 65.5 million customers. The company was founded in 1994 and is headquartered in Bellevue, Washington. T-Mobile US, Inc. operates as a subsidiary of Deutsche Telekom Holding B.V.

Boston Scientific Corporation (BSX) gained $0.45 to close the day at a new closing price of $23.87, a 1.92% increase in value from its previous closing price that moved the stock 52.33% above its 52 week low of $15.67. A total of 6.28M shares exchanged hands during the day compared with its three month average trading volume of 8.61M. The stock, which fluctuated between $23.48 and $23.93 during the day, currently situated -3.71% below its 52 week high. The stock is up by 9.7% in the past one month and up by 8.06% over the past three months. With a one year target estimate of $27.38 and RSI of 70.42, the stock still has upside potential, making it a sell for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Momentum Stocks in Focus: Boston Scientific Corporation (BSX), U.S. Bancorp (USB), PayPal Holdings, Inc. (PYPL)

Boston Scientific Corporation (BSX) managed to rebound with the stock climbing 0.17% or $0.04 to close the day at $23.58 on active trading volume of 9.12M shares, compared to its three month average trading volume of 8.89M. The Marlborough Massachusetts 01752 based company has been outperforming the medical appliances & equipment group over the past 52 weeks, with the stock gaining 35.67%, compared to the industry which has advanced 12.55% over the same period. With RSI of 68.04, the stock should still continue to rise and get closer to its one year target estimate of $27.55, making it a hold for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

U.S. Bancorp (USB) grew with the stock adding 1.31% or $0.68 to close at $52.45 on active trading volume of 8.71M compared its three months average trading volume of 7.6M. The Minneapolis Minnesota 55402 based company operating under the Regional – Midwest Banks industry has been trending up for the last 52 weeks, with the shares price now 37.8% up for the period and up by 2.1% so far this year. With price target of $54 and a 45.04% rebound from 52-week low, U.S. Bancorp has plenty of upside potential, making it a hold with a view buy.

U.S. Bancorp, a financial services holding company, provides a range of financial services in the United States. It offers depository services, which include checking accounts, savings accounts, and time certificate contracts; and lending services, such as traditional credit products, as well as credit card services, leasing financing, import/export trade, asset-backed lending, agricultural finance, and other products. The company also provides ancillary services, including capital markets, treasury management, and receivable lock-box collection services to corporate customers; and a range of asset management and fiduciary services for individuals, estates, foundations, business corporations, and charitable organizations. In addition, it offers investment and insurance products to the company’s customers principally within its markets, as well as fund administration services to a range of mutual and other funds. Further, the company provides corporate and purchasing card, and corporate trust services; and merchant processing services, as well as offers cash and investment management, ATM processing, mortgage banking, and brokerage and leasing services. It serves individuals, businesses, institutional organizations, governmental entities, and other financial institutions. The company offers its services through a network of 3,133 banking offices primarily in the Midwest and West regions of the United States; and a network of 4,936 ATMs, as well as through on-line services and over mobile devices. U.S. Bancorp was founded in 1863 and is headquartered in Minneapolis, Minnesota.

PayPal Holdings, Inc. (PYPL) failed to extend gains with the stock declining -0.6% or $-0.25 to close the day at $41.71 on higher than average trading volume of 8.61M shares, compared to its three month average trading volume of 6.93M. The San Jose California 95131 based company has been outperforming the credit services companies by -4.9872% for last three months and its recent losses have trimmed gains to 5.68% YTD, versus the credit services industry which is up 4.35% for the same period. The RSI of 61.49 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

 

Three Movers to Watch for: NIKE, Inc. (NKE), Opko Health, Inc. (OPK), Boston Scientific Corporation (BSX)

NIKE, Inc. (NKE) grew with the stock adding 0.39% or $0.21 to close at $53.45 on light trading volume of 6.27M compared its three months average trading volume of 9.22M. The Beaverton Oregon 97005 based company operating under the Textile – Apparel Footwear & Accessories industry has been trending down for the last 52 weeks, with the shares price now -10.89% down for the period and up by 5.15% so far this year. With price target of $62 and a 9.45% rebound from 52-week low, NIKE, Inc. has plenty of upside potential, making it a hold with a view buy.

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, and accessories worldwide. It offers products in nine categories, including running, NIKE basketball, the Jordan brand, football, men’s training, women’s training, action sports, sportswear, and golf. The company also markets products designed for kids, as well as for other athletic and recreational uses, such as cricket, lacrosse, tennis, volleyball, wrestling, walking, and outdoor activities. In addition, it sells sports apparel; and markets apparel with licensed college and professional team and league logos. Further, the company sells a line of performance equipment, including bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, golf clubs, and other equipment under the NIKE brand name for sports activities; various plastic products to other manufacturers; athletic and casual footwear, apparel, and accessories under the Jumpman trademark; action sports and youth lifestyle apparel and accessories under the Hurley trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. Additionally, it licenses agreements that permit unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores, sporting goods stores, athletic specialty stores, department stores, skate, tennis and golf shops, and other retail accounts through NIKE-owned retail stores and Internet Websites (direct to consumer operations), as well as independent distributors and licensees. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Opko Health, Inc. (OPK) dropped $-0.06 to close the day at a new closing price of $8.46, a -0.7% decrease in value from its previous closing price that moved the stock 14.02% above its 52 week low of $7.42. A total of 6.25M shares exchanged hands during the day compared with its three month average trading volume of 4.68M. The stock, which fluctuated between $8.42 and $8.62 during the day, currently situated -30.37% below its 52 week high. The stock is down by -28.% in the past one month and down by -9.9% over the past three months. With a one year target estimate of $15.5 and RSI of 29.12, the stock still has upside potential, making it a buy for now.

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States, Ireland, Chile, Spain, Israel, and Mexico. Its diagnostics business operates Bio-Reference Laboratories, a clinical laboratory that offers comprehensive laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units. The Bio-Reference Laboratories also provides core genetic testing and leverages products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment features Rayaldee, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency and VARUBI for chemotherapy-induced nausea and vomiting. Its biologics business engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product under development for the treatment of growth hormone deficiency, and developing Factor VIIa drug for hemophilia using the carboxl terminal peptide technology. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Boston Scientific Corporation (BSX) shares were down in last trading by -0.59% to $23.54. It experienced lighter than average volume on day. The stock decreased in value by almost -1.51% over the past week and grew 9.59% in the past month. It is currently trading 8.31% above its 50 day moving average and 4.31% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -5.04% decrease in value from its one year high of $24.79. The RSI indicator value of 67.88, lead us to believe that it is a hold for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Stocks on Trader’s Radar: The Home Depot, Inc. (HD), Boston Scientific Corporation (BSX), McDonald’s Corporation (MCD)

The Home Depot, Inc. (HD) continued its upward trend with the stock climbing 1.82% or $2.47 to close the day at $138.07 on active trading volume of 7.03M shares, compared to its three month average trading volume of 5.23M. The Atlanta Georgia 30339 based company has been outperforming the home improvement stores group over the past 52 weeks, with the stock gaining 14.87%, compared to the industry which has advanced 11.83% over the same period. With RSI of 66.92, the stock should still continue to rise and get closer to its one year target estimate of $148.08, making it a hold for now.

The Home Depot, Inc. operates as a home improvement retailer. It operates The Home Depot stores that sell various building materials, home improvement products, and lawn and garden products, as well as provide installation, home maintenance, and professional service programs to do-it-yourself, do-it-for-me (DIFM), and professional customers. The company offers installation programs that include flooring, cabinets, countertops, water heaters, and sheds; and professional installation in various categories sold through its in-home sales programs, such as roofing, siding, windows, cabinet refacing, furnaces, and central air systems, as well as acts as a contractor to provide installation services to its DIFM customers through third-party installers. It primarily serves home owners; and renovators/remodelers, general contractors, repairmen, installers, small business owners, and tradesmen. The company also sells its products through online. As of December 31, 2015, it had 2,274 stores, including 1,977 in the United States, 182 in Canada, and 115 in Mexico. The Home Depot, Inc. was founded in 1978 and is based in Atlanta, Georgia.

Boston Scientific Corporation (BSX) fell -0.92% during last trading as the stock lost $-0.22 to finish the day at $23.68 with about 7.03M shares changing hands, compared to its three month average trading volume of 8.94M. The $32.22B market cap company, which fluctuated between $23.53 and $23.88 during the day, currently situated 51.12% above its 52 week low of $15.67 and -4.48% away from its one year high of $24.79. The RSI of 69.71 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

McDonald’s Corporation (MCD) saw its value decrease by -0.72% as the stock dropped $-0.88 to finish the day at a closing price of $121.38. The stock was higher in trading and has fluctuated between $110.33-$131.96 per share for the past year. The shares, which traded within a range of $119.82 to $122.08 during the day, are up by 10.63% in the past three months and down by -3.89% over the past six months. It is currently trading -0.3% below its 20 day moving average and 0.94% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $128.52 a share over the next twelve months. The current relative strength index (RSI) reading is 50.04. The technical indicator lead us to believe there will be no major movement any time soon, hold.

McDonald’s Corporation operates and franchises McDonald’s restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, and Latin America. The company’s restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2015, it operated 36,525 restaurants, including 30,081 franchised restaurants comprising 21,147 franchised to conventional franchisees, 5,529 licensed to developmental licensees, and 3,405 licensed to foreign affiliates; and 6,444 company-operated restaurants. The company has strategic partnerships with CITIC Limited, CITIC Capital, and The Carlyle Group to expand its business in Mainland China and Hong Kong. McDonald’s Corporation was founded in 1940 and is based in Oak Brook, Illinois.